Most Read Articles
Dr Margaret Shi, 14 Nov 2019

The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.

Pank Jit Sin, 30 Oct 2017
Barely has the dust settled on e-cigarettes before the next cigarette replacement product, based on the heat-not-burn (HNB) principle, emerges to derail tobacco control efforts. 
Natalia Reoutova, 18 Sep 2019

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

6 days ago
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 

Nasal polyps linked to nasal cancers in seniors

11 Oct 2019

Elderly adults with nasal polyps suffer from elevated relative risks of nasopharyngeal and nasal cavity and paranasal sinus (NCPS) cancers, a recent study has found.

The longitudinal retrospective study included 453,892 participants (59.45 percent male) with nasal polyps and 4,583,938 matched comparators (59.45 percent male). Cancers of the nasopharynx and the NCPS were the study’s primary outcomes, while malignancies of the larynx and hypopharynx were also included in the analysis.

Over a mean follow-up of 6.2 years, the annual crude incidence rates of NCPS and nasopharyngeal cancers in participants with nasal polyps were 2.66 and 1.46 per 100,000 person-years, respectively. Hypopharyngeal and laryngeal malignancies, in comparison, had rates of 0.87 and 3.14 per 100,000 person-years.

Patients with nasal polyps were significantly more likely to develop NCPS (incidence rate ratio [IRR], 7.00, 95 percent CI, 5.28–9.25) and nasopharyngeal (IRR, 1.78, 1.28–2.42) cancers than their matched comparators. The corresponding risk estimates for laryngeal and hypopharyngeal malignancies failed to reach statistical significance.

Multivariate Cox regression analysis confirmed the positive association between nasal polyps and risks of NCPS (adjusted hazard ratio [HR], 6.24, 4.70–8.28) and nasopharyngeal (adjusted HR, 1.58, 1.16–2.16) cancers.

Subsequent subgroup analyses found that nasal polyps were reliably correlated with the risk of NCPS cancer in participants at least 50 years of age, regardless of asthma comorbidity (with: adjusted HR, 4.84, 1.86–12.59; without: adjusted HR, 7.48, 5.30–10.54).

A similar pattern of effect was observed for nasopharyngeal cancer, though the lack of asthma comorbidity attenuated its significant relationship with nasal polyps regardless of age.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 14 Nov 2019

The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.

Pank Jit Sin, 30 Oct 2017
Barely has the dust settled on e-cigarettes before the next cigarette replacement product, based on the heat-not-burn (HNB) principle, emerges to derail tobacco control efforts. 
Natalia Reoutova, 18 Sep 2019

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

6 days ago
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.